PARIS, Feb 27 (Reuters) - French drugmaker Sanofi and Switzerland’s Lonza will invest 270 million euros ($285 million) to build a large-scale biologics facility that will produce monoclonal antibodies by 2020, the two companies said on Monday.
Pending regulatory approvals, the facility, which will be established through a 50-50 joint venture, will be located in Visp, Switzerland, Sanofi and Lonza said in a joint statement.
By contrast to most drugs that are chemically synthesized, many biologics are produced using living cells. They are seen as a promising answer in areas such as cardiovascular, neurology or cancer treatments.
$1 = 0.9471 euros Reporting by Matthias Blamont; editing by Jason Neely